Researchers tested a drug called diacerein on mice with genetic conditions that cause fatty liver disease and heart problems. The drug works by reducing inflammation in the body. When mice took diacerein, they developed less fat in their livers, less scarring of liver tissue, and fewer fatty deposits in their arteries. The benefits increased with higher doses of the drug. While these results are exciting, this research was done in mice, so scientists will need to test whether the drug works safely and effectively in people before it can be used as a treatment.
The Quick Take
- What they studied: Whether a drug called diacerein could reduce fat buildup in the liver, liver scarring, and artery disease in mice with genetic conditions that make them prone to these problems
- Who participated: Laboratory mice that were genetically modified to lack a protein called apolipoprotein E, which made them develop fatty liver disease and heart disease when fed a high-fat diet
- Key finding: Mice treated with diacerein had significantly less fat in their livers, less liver scarring, and smaller fatty deposits in their arteries compared to untreated mice, with better results at higher doses
- What it means for you: This research suggests diacerein might one day help people with fatty liver disease and heart disease, but much more testing in humans is needed before it could become a treatment option
The Research Details
Scientists used genetically modified mice that naturally develop fatty liver disease and artery problems similar to those seen in humans. They fed these mice a high-fat diet to make their conditions worse, then divided them into groups receiving different amounts of diacerein or no treatment. Over the study period, researchers examined the mice’s livers and arteries to see how much fat and scarring had developed.
The researchers looked at several things: how much fat accumulated in liver cells, how much the liver tissue had scarred (a sign of advanced liver damage), and how much fatty plaque built up in the arteries. They also studied the genes that were turned on or off in the liver tissue to understand how the drug was working at a molecular level.
To understand the mechanism better, scientists also did laboratory experiments with cells to confirm how diacerein affects the inflammatory pathways involved in these diseases.
This study design is important because it uses mice that naturally develop the same diseases humans get, making the results more relevant to human health. By testing different doses, researchers could see if higher amounts of the drug worked better, which is crucial information for future human trials. The combination of looking at physical changes in organs plus studying the underlying genetic and molecular changes provides a complete picture of how the drug works.
This is a controlled laboratory study published in a peer-reviewed scientific journal, which means other experts reviewed the work before publication. The researchers used established methods for examining liver tissue and measuring artery disease. However, because this is animal research, results may not translate directly to humans. The study doesn’t specify exactly how many mice were used in each group, which would help readers assess the strength of the findings.
What the Results Show
Diacerein treatment reduced the amount of fat stored in liver cells in a dose-dependent manner, meaning higher doses led to greater reductions in liver fat. The drug also decreased liver scarring (fibrosis), which is a sign of more advanced liver damage. Importantly, these improvements happened even though the mice were still eating a high-fat diet, suggesting the drug actively counteracts the harmful effects of unhealthy eating.
The researchers found that diacerein reduced the expression of genes related to liver scarring and fibrosis. This is significant because it shows the drug isn’t just treating symptoms but is actually changing how the liver responds to injury at the genetic level.
In the arteries, diacerein treatment reduced the buildup of fatty plaques (atherosclerosis), which is the process that leads to heart attacks and strokes. The drug also lowered levels of inflammatory molecules called cytokines, particularly TNF-α, which are known to drive both liver disease and heart disease.
The study found that diacerein’s benefits appeared to work through reducing inflammation throughout the body. By lowering inflammatory signals, the drug seemed to protect both the liver and blood vessels from damage. The dose-dependent response (more drug = more benefit) suggests there may be an optimal treatment level that could be determined in future studies. The researchers also noted that the drug’s effects on genes related to fat metabolism suggest it may help the body process fats more efficiently.
This research builds on earlier findings showing that chronic inflammation plays a central role in both fatty liver disease and atherosclerosis (artery disease). Previous studies suggested these two conditions share common inflammatory pathways, and this work confirms that targeting inflammation with diacerein can improve both conditions simultaneously. The findings align with growing interest in anti-inflammatory drugs as treatments for metabolic diseases.
This study was conducted only in mice, and mouse biology doesn’t always match human biology, so results may not translate directly to people. The study doesn’t specify the exact number of mice used in each group, making it harder to assess how reliable the findings are. The research was done in mice with a specific genetic modification, so results may not apply to people with fatty liver disease from other causes. Additionally, the study only looked at short-term effects, so it’s unknown whether the benefits would continue long-term or if side effects might develop with extended use.
The Bottom Line
Based on this animal research, diacerein shows promise as a potential treatment for fatty liver disease and related heart disease, but it is not yet ready for human use. Anyone interested in treating fatty liver disease should continue following their doctor’s current recommendations, which typically include weight loss, reducing sugar and fat intake, and increasing physical activity. This research suggests diacerein could be a candidate for future clinical trials in humans, but those trials have not yet been conducted.
This research is most relevant to people with non-alcoholic fatty liver disease (NAFLD) and those at risk for atherosclerosis or heart disease. It may also interest people with metabolic syndrome or obesity. However, because this is early-stage animal research, it should not influence current treatment decisions. Healthcare providers and pharmaceutical researchers should pay attention to these findings as they consider which drugs to test in human trials next.
Since this is animal research, there is no timeline for human benefits yet. If diacerein moves forward to human clinical trials, it typically takes 5-10 years of testing before a new drug could become available to patients. Even if human trials are successful, regulatory approval and availability would take additional time.
Want to Apply This Research?
- Users could track liver health markers by logging any available lab results (ALT, AST, or ultrasound findings) every 3-6 months and noting any changes in energy levels, abdominal bloating, or digestive symptoms that might indicate liver function changes
- Users should focus on the proven interventions for fatty liver disease: reduce added sugars and refined carbohydrates, increase physical activity to 150 minutes per week, and track weight loss progress. Users can set reminders for regular doctor visits to monitor liver health through blood tests
- Establish a baseline of current liver health through doctor’s tests, then monitor changes quarterly through follow-up appointments. Track dietary improvements and exercise consistency weekly through the app, and note any symptoms like fatigue or abdominal discomfort that might indicate liver stress
This research was conducted in laboratory mice and has not been tested in humans. Diacerein is not currently approved for treating fatty liver disease or heart disease in any country. This article is for educational purposes only and should not be used to make treatment decisions. Anyone with fatty liver disease or concerns about heart disease should consult with their healthcare provider about proven treatment options, which currently include lifestyle changes such as weight loss, dietary modifications, and increased physical activity. Do not start, stop, or change any medications without medical supervision.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.